Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

804
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
804
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

1.9K
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.9K
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

344
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
344

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hypersensitivity to Psychotropic Medications in a Patient With 17q12 Microdeletion Syndrome: A Case Report.

Journal of clinical psychopharmacology·2023
Same author

Letter to the Editor: Protracted Neutropenia After Treatment With Non-Clozapine Antipsychotic Medications.

Journal of clinical psychopharmacology·2022
Same author

Catatonia and Schizophrenia in a Young Man with Autism Spectrum Disorder and Clozapine-Induced Myocarditis.

Harvard review of psychiatry·2022
Same author

A 6-year retrospective review of psychiatric emergency service utilization by school-age children.

Clinical child psychology and psychiatry·2022
Same author

Compulsivity in Intractable Idiopathic Generalized Epilepsy.

Journal of the Academy of Consultation-Liaison Psychiatry·2022
Same author

Case Report: Clozapine-Induced Myocarditis in a Patient with Autism Spectrum Disorder and Schizophrenia.

Journal of autism and developmental disorders·2021

Related Experiment Video

Updated: Mar 18, 2026

Examining the Characteristics of Episodic Memory using Event-related Potentials in Patients with Alzheimer's Disease
11:01

Examining the Characteristics of Episodic Memory using Event-related Potentials in Patients with Alzheimer's Disease

Published on: August 30, 2011

14.2K

Donepezil for Korsakoff Syndrome.

Marisa Fallone1, Mauran Sivananthan, Melvin Joseph

  • 1Department of Behavioral Health, Henry Ford Health System, Detroit, MI.

American Journal of Therapeutics
|March 17, 2026
PubMed
Summary
This summary is machine-generated.

Donepezil, an Alzheimer disease medication, may improve symptoms of Korsakoff syndrome, a memory disorder caused by thiamine deficiency. This case study suggests potential benefits for cognition and affect in patients with Korsakoff syndrome.

More Related Videos

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

10.3K
Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models
10:46

Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models

Published on: May 3, 2017

11.8K

Related Experiment Videos

Last Updated: Mar 18, 2026

Examining the Characteristics of Episodic Memory using Event-related Potentials in Patients with Alzheimer's Disease
11:01

Examining the Characteristics of Episodic Memory using Event-related Potentials in Patients with Alzheimer's Disease

Published on: August 30, 2011

14.2K
A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

10.3K
Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models
10:46

Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models

Published on: May 3, 2017

11.8K

Area of Science:

  • Neuroscience
  • Neurology

Background:

  • Korsakoff syndrome is a severe neurocognitive disorder resulting from thiamine deficiency.
  • It is characterized by memory impairment and confabulation.
  • Wernicke's encephalopathy precedes Korsakoff syndrome and is reversible, but Korsakoff syndrome has limited treatment options.

Purpose of the Study:

  • To investigate the potential benefits of donepezil in a patient with Korsakoff syndrome.
  • To explore off-label therapeutic options for Korsakoff syndrome.

Main Methods:

  • Case study based on clinical records and direct patient observations.
  • Retrospective analysis of patient's response to donepezil treatment.

Main Results:

  • The patient with Korsakoff syndrome showed improvement in cognition, motivation, and affect after initiating donepezil.
  • Donepezil was well-tolerated in this case.

Conclusions:

  • Off-label use of donepezil may be beneficial for managing symptoms of Korsakoff syndrome.
  • Larger studies are required to confirm the safety and efficacy of donepezil for Korsakoff syndrome.